Loading clinical trials...
Loading clinical trials...
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Conditions
Interventions
62.5/25mcg
62.5mcg
+2 more
Locations
165
United States
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Ormond Beach, Florida, United States
GSK Investigational Site
Tampa, Florida, United States
GSK Investigational Site
Atlanta, Georgia, United States
GSK Investigational Site
Lawrenceville, Georgia, United States
Start Date
March 1, 2011
Primary Completion Date
April 1, 2012
Completion Date
April 5, 2012
Last Updated
August 6, 2018
NCT06712563
NCT07518472
NCT06831994
NCT05730088
NCT02755974
NCT07363980
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions